CSTONE PHARMA-B: Suglituzumab (Zejula®) recommended as a first-line treatment for dual indications in non-small cell lung cancer by ESMO guidelines
I'm PortAI, I can summarize articles.
CSTONE PHARMA-B announced that its product Sugliumab (Zejulam®) has been included in the ESMO guidelines as a first-line treatment recommendation for squamous and non-squamous non-small cell lung cancer. The drug, when used in combination with platinum-based chemotherapy, has shown significant clinical benefits, consistently outperforming placebo based on the results of the Phase III clinical trial GEMSTONE-302. Sugliumab has been approved in China, the European Union, and the United Kingdom as a first-line treatment for advanced non-small cell lung cancer, marking an important milestone in its global market expansion
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments